title: Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia.
abstract: Forty-six patients with chronic myeloid leukemia receiving imatinib mesylate (39 in chronic phase, one in accelerated phase, and six in blastic crisis), were studied for a 20-62 month follow-up period by cytogenetics and fluorescence in situ hybridization using dual-color, dual-fusion BCR and ABL probes. This approach provided valuable results for disease management of analysis.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Calabrese
authors.forename: Donatella
authors.initials: D
authors.lastname: Fantasia
authors.forename: Rita
authors.initials: R
authors.lastname: Di Gianfilippo
authors.forename: Liborio
authors.initials: L
authors.lastname: Stuppia
authors.forename: Roberto
authors.initials: R
authors.lastname: Di Lorenzo
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Palka
mesh_terms: D001549:Benzamides; D002872:Chromosome Deletion; D002899:Chromosomes, Human, Pair 9; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate